Clinical effect and safety evaluation of hydromorphone combined with sufentanil in patient‑controlled intravenous analgesia for patients with hepatocellular cancer and its effect on serum immune factors

Liu,Jitong; Wang,Yongsheng; Tang,Yixun; Luo,Jia; Long,Yi; Tan,Suhong

doi:10.3892/ol.2020.12159

Clinical effect and safety evaluation of hydromorphone combined with sufentanil in patient‑controlled intravenous analgesia for patients with hepatocellular cancer and its effect on serum immune factors

Authors:
- Jitong Liu
- Yongsheng Wang
- Yixun Tang
- Jia Luo
- Yi Long
- Suhong Tan
View Affiliations

Affiliations: Department of Anesthesiology, Hunan Provincial People's Hospital, Changsha, Hunan 410005, P.R. China
Published online on: September 25, 2020 https://doi.org/10.3892/ol.2020.12159
Article Number: 296

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the clinical efficacy and safety of hydromorphone combined with sufentanil in patient‑controlled intravenous analgesia (PCIA) for patients with hepatocellular carcinoma (HCC) and its effect on serum immune factors in serum. Data from 385 patients with HCC, admitted to the Hunan Provincial People's Hospital (Changsha, China) from February 2015 to September 2018, were retrospectively analyzed. Laparoscopic hepatectomy was performed in all patients. A total of 180 patients who received PCIA were treated with sufentanil (control group), and 205 patients who received PCIA were treated with hydromorphone and sufentanil (study group). PCIA was used after hepatocellular cancer operation. In the control group, the analgesic pump was filled with sufentanil (2 µg/kg) and tropisetron (5 mg), whereas in the study group, the analgesic pump was filled with sufentanil (2 µg/kg), tropisetron (5 mg) and hydromorphone (5 mg). Both groups of drugs were diluted into 100 ml with normal saline and the loading dose was 5 ml; the continuous dose was 2 ml/h and the single PCIA amount was 2 ml. The visual analogue scale (VAS) and numeric sedation scale (NSS) scores at 12 and 24 h after operation, as well as and satisfaction score at 24 h after operation, were recorded. The levels of CD3+, CD4+, CD8+ lymphocytes and NK cells in the peripheral blood of patients were detected by flow cytometry. The postoperative hospitalization time, first flatulence time, first defecation time and first ambulation time, as well as the adverse reactions, were recorded. The results revealed that the satisfaction score of the patients at 24 h after operation was significantly higher in the study group than that in the control group (P<0.05). Additionally, there were no serious adverse reactions in either group. In conclusion, PCIA with hydromorphone and sufentanil can provide safe and effective analgesia, may improve the levels of immune factors and enhance the recovery ability of the patients.

View Figures

View References

1	Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, et al: Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 122:1312–1337. 2016. View Article : Google Scholar : PubMed/NCBI
2	Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, Yan X, Ye B, Li C, Xia P, et al: The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell. 16:413–425. 2015. View Article : Google Scholar : PubMed/NCBI
3	Hu XY, Hou PF, Li TT, Quan HY, Li ML, Lin T, Liu JJ, Bai J and Zheng JN: The roles of Wnt/β-catenin signaling pathway related lncRNAs in cancer. Int J Biol Sci. 14:2003–2011. 2018. View Article : Google Scholar : PubMed/NCBI
4	Lee MW and Lim HK: Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. World J Gastroenterol. 24:5215–5222. 2018. View Article : Google Scholar : PubMed/NCBI
5	Chen X, Sun Y, Cai R, Wang G, Shu X and Pang W: Long noncoding RNA: Multiple players in gene expression. BMB Rep. 51:280–289. 2018. View Article : Google Scholar : PubMed/NCBI
6	Zhao X, Sun B, Liu T, Shao B, Sun R, Zhu D, Zhang Y, Gu Q, Dong X, Liu F, et al: Long noncoding RNA n339260 promotes vasculogenic mimicry and cancer stem cell development in hepatocellular carcinoma. Cancer Sci. 109:3197–3208. 2018. View Article : Google Scholar : PubMed/NCBI
7	Brogan SE, Winter NB and Okifuji A: Prospective observational study of patient-controlled intrathecal analgesia: Impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction. Reg Anesth Pain Med. 40:369–375. 2015. View Article : Google Scholar : PubMed/NCBI
8	Li Z, Wu H, He R, Hu X and Liu S: Oxycodone versus dezocine for postoperative analgesia in patients with cervical cancer treated with radical surgery. J Cancer Res Ther. 12 (Suppl 1):S27–S29. 2016. View Article : Google Scholar
9	Lu YY, Huang H, Mao WL, Liu RH, Hu MJ, Shao LX, Hu MP and Li J: A concentration-response observation of hydromorphone combined with ropivacaine in labor analgesia. Zhonghua Yi Xue Za Zhi. 97:3297–3300. 2017.(In Chinese). PubMed/NCBI
10	Bhatia N, Mehta S, Saini V, Ghai B and Kaman L: Comparison of intraperitoneal nebulization of ropivacaine with ropivacaine-fentanyl combination for pain control following laparoscopic cholecystectomy: A randomized, double-blind, placebo-controlled trial. J Laparoendosc Adv Surg Tech A. 28:839–844. 2018. View Article : Google Scholar : PubMed/NCBI
11	Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 120:1290–1314. 2014. View Article : Google Scholar : PubMed/NCBI
12	Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Antoni S, et al: Cancer incidence in five continents: Inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer. 137:2060–2071. 2015. View Article : Google Scholar : PubMed/NCBI
13	Du H, Le Y, Sun F, Li K and Xu Y: ILF2 directly binds and stabilizes CREB to stimulate malignant phenotypes of liver cancer cells. Anal Cell Pathol (Amst). 2019:15750312019.PubMed/NCBI
14	Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, Pan L, Anderson RN, Fulton JE, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 118:2338–2366. 2012. View Article : Google Scholar : PubMed/NCBI
15	Yang XH, Bai Q, Lv MM, Fu HG, Dong TL and Zhou Z: Effect of dexmedetomidine on immune function of patients undergoing radical mastectomy: A double blind and placebo control study. Eur Rev Med Pharmacol Sci. 21:1112–1116. 2017.PubMed/NCBI
16	Sayed JA, Abd Elshafy SK, Kamel EZ, Fathy Riad MA, Mahmoud AA and Khalaf GS: The impact of caudally administered tramadol on immune response and analgesic efficacy for pediatric patients: A comparative randomized clinical trial. Korean J Pain. 31:206–214. 2018. View Article : Google Scholar : PubMed/NCBI
17	Dong W, Chen MH, Yang YH, Zhang X, Huang MJ, Yang XJ and Wang HZ: The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer. Eur Rev Med Pharmacol Sci. 21:3510–3515. 2017.PubMed/NCBI
18	Peng Z, Zhang Y, Guo J, Guo X and Feng Z: Patient-controlled intravenous analgesia for advanced cancer patients with pain: A retrospective series study. Pain Res Manag. 2018:73235812018. View Article : Google Scholar : PubMed/NCBI
19	Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, et al: Annual report to the Nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 105:175–201. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kim KH: Neurourological application of neurogenesis and inflammation and pain mechanisms of rocuronium bromide. Int Neurourol J. 20:274–275. 2016. View Article : Google Scholar : PubMed/NCBI
21	Kurozumi S, Matsumoto H, Kurosumi M, Inoue K, Fujii T, Horiguchi J, Shirabe K, Oyama T and Kuwano H: Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett. 17:2647–2656. 2019.PubMed/NCBI
22	Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al: Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 232:199–209. 2014. View Article : Google Scholar : PubMed/NCBI
23	Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, et al: Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 4:419–430. 2016. View Article : Google Scholar : PubMed/NCBI
24	Sun C, Xu J, Song J, Liu C, Wang J, Weng C, Sun H, Wei H, Xiao W, Sun R and Tian Z: The predictive value of centre tumour CD8⁺ T cells in patients with hepatocellular carcinoma: Comparison with Immunoscore. Oncotarget. 6:35602–35615. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kwak Y, Koh J, Kim DW, Kang SB, Kim WH and Lee HS: Immunoscore encompassing CD3⁺ and CD8⁺ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget. 7:81778–81790. 2016. View Article : Google Scholar : PubMed/NCBI
26	Barnes TA and Amir E: HYPE or HOPE: The prognostic value of infiltrating immune cells in cancer. Br J Cancer. 117:451–460. 2017. View Article : Google Scholar : PubMed/NCBI